Neuphoria Therapeutics Inc. Common Stock (NEUP) Stock Price

NEUPStock

$3.86−44.99%52W

Market Cap$20.86M

P/E—

PEG Ratio—

Div yield—

Beta0.77

NEUP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-21.88%

Price vs S&P 500 (4W)0.62%

VGM Score41.03

P/CF (Annual)268.13x

Book Value / Share (Quarterly)$5.47

P/TBV (Annual)0.94x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)696.24%

Cash Flow / Share (Quarterly)$-3.19

Price vs S&P 500 (YTD)-10.15%

Net Profit Margin (TTM)59.50%

EPS (TTM)$-8.77

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-8.77

EPS (Annual)$-0.23

ROI (Annual)-1.94%

Cash / Share (Quarterly)$3.62

ROA (Last FY)-1.29%

Revenue Growth TTM (YoY)-27.00%

EBITD / Share (TTM)$-4.57

Operating Margin (TTM)52.82%

Cash Flow / Share (Annual)$0.04

P/B Ratio0.70x

P/B Ratio (Quarterly)0.75x

Net Income / Employee (Annual)$-52,900

Net Interest Coverage (TTM)-2.37x

ROA (TTM)-54.76%

EPS Incl Extra (Annual)$-0.23

Current Ratio (Annual)3.56x

Quick Ratio (Quarterly)13.91x

3-Month Avg Trading Volume0.15M

52-Week Price Return-44.99%

EV / Free Cash Flow (Annual)16.75x

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.67

P/S Ratio (Annual)1.32x

Asset Turnover (Annual)0.55x

52-Week High$21.40

EPS Excl Extra (Annual)$-0.23

26-Week Price Return-10.63%

Quick Ratio (Annual)3.39x

13-Week Price Return-22.85%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)14.31x

Enterprise Value$1.29M

Asset Turnover (TTM)0.64x

Revenue / Employee (Annual)$2,235,600

Pretax Margin (Annual)-5.35%

Cash / Share (Annual)$7.18

3-Month Return Std Dev68.79%

Net Income / Employee (TTM)$-2,490,200

ROE (Last FY)-1.95%

Net Interest Coverage (Annual)-9.14x

EPS Basic Excl Extra (Annual)$-0.23

Receivables Turnover (TTM)0.76x

EV / Free Cash Flow (TTM)13.82x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-8.77

Receivables Turnover (Annual)2.60x

ROI (TTM)-76.81%

P/S Ratio (TTM)1.32x

Revenue / Share (Annual)$9.64

Tangible BV / Share (Annual)$7.18

Price vs S&P 500 (52W)-63.30%

Year-to-Date Return1.80%

5-Day Price Return-0.75%

EPS Normalized (Annual)$-0.23

ROA (5Y Avg)-36.63%

Net Profit Margin (Annual)-2.36%

Month-to-Date Return1.80%

EBITD / Share (Annual)$-0.29

Operating Margin (Annual)-7.21%

P/CF (TTM)32.84x

EPS Basic Excl Extra (TTM)$-8.77

P/TBV (Quarterly)0.87x

P/B Ratio (Annual)0.70x

Pretax Margin (TTM)59.05%

Book Value / Share (Annual)$9.61

Price vs S&P 500 (13W)-25.65%

Beta0.77x

P/FCF (Annual)268.13x

Revenue / Share (TTM)$0.00

ROE (TTM)-76.93%

52-Week Low$3.19

vGradeB

gGradeD

mGradeD

vgmGradeC

NEUP Earnings Surprise History

Q2 25-5.55est. -3.83

Q3 25-4.41est. -1.31

Q4 250.41est. -0.56

Q1 26-0.09est. -0.56

NEUP Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

4.13

2.17

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
NEUPNeuphoria Therapeutics Inc. Common Stock	B	D	D	$3.86
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics is a clinical-stage biotechnology company developing treatments for neuropsychiatric disorders. Its lead candidate, BNC 210, is an oral selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor in development for acute social anxiety disorder and chronic post-traumatic stress disorder. The company focuses on allosteric ion channel modulators targeting central nervous system disorders with significant unmet medical needs.